References
- Fuller RW, Wong DT. Serotonin uptake and serotonin uptake inhibition. Ann N Y Acad Sci 1990; 600: 68–80
- Fuller RW, Wong DT, Robertson DW. Fluoxetine, a selective inhibitor of serotonin uptake. Med Res Rev 1991; 11: 17–34
- Wong DT, Horng TS, Bymaster FL, Hauser KL, Molloey BB. A selective inhibitor of serotonin uptake. Lilly 110140, 3-(p-trifluoro-methylphenoxy)-N-methyl-3-phenyl-propylamine. Life Sci 1974; 15: 471–479
- Cooper GL. The safety of fluoxetine - An update. Br J Psychiatry Suppl 1988; 153: 77–86
- Helper JP, Mann JJ. Cardiovascular effects of antidepressant medications. Br J Psychiatry Suppl 1988; 153: 87–98
- Buff DD, Brenner R, Kirtane SS, Gilboa R. Dysrhythmia associated with fluoxetine treatment in an elderly patient with cardiac disease. J Clin Psychiatry 1991; 52: 174–176
- Ellison J, Ellisa E, Milofsky J. Replay to comment. J Clin Psychiatry 1991; 52: 139
- Gardner S, Rutherford W, Munger M, Panacek E. Drug-induced supraventricular tachycardia: A case report of fluoxetine. Ann Emerg Med 1991; 20: 194–196
- Fisch C. Effect of fluoxetine on the electrodiagram. J Clin Psychiatry 1985; 46: 42–44
- Feder R. Bradycardia and syncope induced by fluoxetine. J Clin Psychiatry 1991; 52: 139
- Asberg M, Thoren P, Traskman L, Bertlisson L, Ringberger W. Serotonin depression: a biochemical subgroup within the affective disorders?. Science 1979; 191: 478–480
- Ellison J, Milofsky J, Ely E. Fluoxetine-induced bradycardia and syncope in two patients. J Clin Psychiatry 1990; 51: 385–386
- Baldwin D, Fineberg N, Montgomery S. Fluoxetine, fluvosamine and extrapyramidal tract disorders. Int Clin Psychopharmacol 1991; 6: 51–58
- Bouchard RH, Pourcher E, Vincent P. Fluoxetine and extrapyramidal side effect. Am J Psychiatry 1989; 146: 1352–1353
- Budman CL, Bruun RD. Persistent dyskinesia in a patient receiving fluoxetine. Am J Psychiatry 1991; 148: 1403
- Caley CF, Friedman JH. Does fluoxetine exacerbate Parkinson's disease?. J Clin Psychiatry 1992; 53: 278–282
- Fallon BA, Liebowitz MR. Fluoxetine and extrapyramidal symptoms in CNS lupus. J Clin Psychopharmacol 1991; 11: 147–148
- Friedman EH. Fluoxetine-induced akathisia in male OCD patients. J Clin Psychiatry 1990; 51: 212
- Lock JD, Gwirtsman HE, Targ EF. Possible adverse drug interactions between fluoxetine and other psychotropics. J Clin Psychopharmacol 1990; 10: 383–384
- Lipinski JE, Mallya G, Zimmerman P, Pope HG. Fluoxetine-induced akathisia: Clinical and theoretical implications. J Clin Psychiatry 1989; 50: 339–342
- Levinson ML, Lipsy RJ, Fuller DK. Adverse effects and drug interactions associated with fluoxetine therapy. DICP 1991; 25: 657–661
- Maany I, Dhopesh V. Akathisia and fluoxetine. J Clin Psychiatry 1990; 51: 210–212
- Meltzer HY, Young M, Metz J, et al. Extrapyramidal side effects and increased serum prolactin following fluoxetine, a new antidepressant. J Neural Transm 1979; 45: 165–175
- Tate JL. Extrapyramidal symptoms in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1989; 146: 399–400
- Austin LS, Arana GW, Melvin JA. Toxicity resulting from lithium augmentation of antidepressant treatment in elderly patient. J Clin Psychiatry 1990; 51: 344–355
- Gernaat HB, Van de Woude J, Touw DJ. Fluoxetine and parkinsonism in patients taking carbamazepine. Am J Psychiatry 1991; 148: 1604–1605
- Stein MH. Tardive dyskinesia in a patient taking haloperidol and fluoxetine. Am J Psychiatry 1991; 148: 683
- Crane GE. A review of clinical literature on haloperidol. Int J Neuropsychiatry 1967; 3: 110–127, Suppl
- Zubenko GS, Cohen BM, Lipinski JF. Antidepressant-induced akathisia. J Clin Psychopharmacol 1987; 7: 254–257
- Reccoppa L, Welch WA, Ware MR. Acute dystonia by fluoxetine. J Clin Psychiatry 1990; 51: 487
- Rotschild AJ, Locke CA. Reexposure to fluoxetine after serious suicide attempts by three patients: The role of akathisia. J Clin Psychiatry 1991; 52: 491–493
- Wirshing WC, Van Putten T, Rosenberg J, et al. Fluoxetine, akathisia and suicidality: Is there a causal connection?. Arch Gen Psychiatry 1992; 49: 580–581
- Baldessarini RJ, Marsh ER, Kula NS. Interaction of fluoxetine with metabolism of dopamine and serotonin in rat brain region. Brain Res 1992; 579: 152–156
- Fleischhacker WW. Propranolol for fluoxetine-induced akathisia. Biol Psychiatry 1991; 30: 531–532
- Black B, Uhde TW. Acute dystonia and fluoxetine. J Clin Psychiatry 1992; 53: 327
- Lee HK. Dystonic reactions to amitriptyline and doxepin. Am J Psychiatry 1988; 145: 649
- McCann UD, Penetar DM, Belenky G. Acute dystonic reaction in normal humans caused by catecholamine depletion. Clin Neuropharmacol 1990; 13: 565–568
- Chouinard G, Sultan A. A case of Parkinson's disease exacerbated by fluoxetine. Human Psychopharmacol 1992; 7: 63–66
- Baldessarini R, Marsh E. Fluoxetine and side effects. Arch Gen Psychiatry 1990; 47: 191–192
- Korsgaard S, Lerlach J, Christensson E. Behavioral aspects of serotonin-dopamine interaction in the monkey. European J Pharmacol 1985; 118: 245–252
- Bartholini G, Da Prada M, Pletcher A. Decrease of cerebral 5-hydroxy-tryptamine by 3,4-dihydroxyphenylalanine after inhibition of extracerebral decarboxylase. J Pharm Pharmacol 1968; 20: 228–229
- Ng KY, Chase TN, Colburn RW. Dopa-induced release of cerebral monoamines. Science 1970; 170: 76–77
- Messiha FS, Knopp W. Metabolic patterns and clinical response to levodopa therapy in Parkinson's disease. Clin Pharmacol Ther 1973; 14: 565–571
- Beasley CM, Masica DN, Potvin JH. Fluoxetine: A review of receptor and functional effects and their clinical implications. Psychopharmacology 1992; 107: 1–10
- Bockaert J, Fozard J, Dumuis A, Clarke D. The 5-HT4 receptor: A place in the sun. Trends Pharmacol Sci 1992; 13: 141–145
- Fuller RW. Basic advances in serotonin pharmacology. J Clin Psychiatry 1992; 53: 36–45, Suppl
- Peters JA, Malone HM, Lambert JJ. Recent advances in the electro-physiological characterization of 5-HT3 receptors. Trends Pharmacol Sci 1992; 13: 391–397
- Hoyer D, Schoeffter P, Waeber C, Palacios JM. Serotonin 5-HT1D receptors. Ann N Y Acad Sci 1990; 600: 168–181
- Hoyer D. Serotonin 5-HT3, 5-HT4 and 5-HT-M receptors. Neuro-psychopharmacol 1990; 3: 371–383
- Chouinard G, Steiner W. A case of mania induced by high-dose fluoxetine treatment. Am J Psychiatry 1986; 143: 686
- Feder R. Fluoxetine-induced mania. J Clin Psychiatry 1990; 51: 524–525
- Hon D, Preskon SH. Mania during fluoxetine treatment for recurrent depression. Am J Psychiatry 1989; 146: 1638–1639
- Jerome L. Hypomania with fluoxetine. J Am Acad Child Adoles Psychiatry 1991; 30: 850–851
- Lebegue B. Mania precipitated by fluoxetine. Am J Psychiatry 1987; 144: 1620
- Lensgraf SJ, Favazza AR. Antidepressant-induced mania. Am J Psychiatry 1990; 147: 1569
- Vakra BR, Szwabo P, Grossberger GT. Mania induced by fluoxetine. Am J Psychiatry 1989; 146: 1515–1516
- Piredda SG, Rubinstein SL. Hypomania induced by fluoxetine. Biol Psychiatry 1992; 32: 107
- Settle EC, Settle GP. A case of mania associated with fluoxetine. Am J Psychiatry 1984; 141: 280–281
- Nakra B, Szwabo P, Grossberg G. Mania induced by fluoxetine. Am J Psychiatry 1989; 146: 1515–1516
- Achamallah NS, Decker DH. Mania-induced by fluoxetine in an adolescent patient. Am J Psychiatry 1991; 148: 1404
- Venkatarman S, Naylor MW, King CA. Mania associated with fluoxetine treatment in adolescents. J Am Acad Child Adoles Psychiatry 1992; 31: 276–281
- Jefferson J, Greist J, Perse T, Rosenfeld R. Fluoxetine-associated mania/hypomania in patients with obsessive-compulsive disorder. J Clin Psychopharmacol 1991; 11: 391–392
- Hadley A, Cason MP. Mania resulting from lithium-fluoxetine combination. Am J Psychiatry 1989; 146: 1637–1638
- Pohland RC, Byrd T, Hamilton M, Koons J. Placental and fetal distribution of fluoxetine in the rat. Toxicol Appl Pharmacol 1989; 98: 198–205
- Cool DR, Liebach FH, Ganapathy V. Interaction of fluoxetine with the human placental serotonin transporter. Biochem Pharmacol 1990; 40: 2161–2167
- Burch KJ, Wells BG. Fluoxetine/norfluoxetine concentrations in human milk. Pediatrics 1992; 98: 676–677
- Schader RI. A patient of mine missed a period while taking fluoxetine; it turned out that she was not pregnant. However, the question arose about the safety of fluoxetine during pregnancy. What is known?. J Clin Psychopharmacol 1992; 12: 213
- Bass SP, Colebatch H JH. Fluoxetine-induced lung damage. Med J Austral 1992; 156: 364
- Harrison WA, Rabkin JG, Erhardt A, et al. Effects of antidepressant medication on sexual function. J Clin Psychopharmacol 1989; 6: 933–934
- Cole JO, Bodkin JA. Antidepressant side effects. J Clin Psychiatry 1990; 5: 21–26, Suppl
- Swensson L, Hanson S. Spinal nonadrenergic modulation of masculine copulatory behavior in the rat. Brain Res 1984; 302: 315–321
- Zajecka J, Fawcett F, Schoff M, et al. The role of serotonin in sexual dysfunction: Fluoxetine-associated orgasm dysfunction. J Clin Psychiartry 1991; 52: 66–68
- Herman JB, Brotman AW, Pollack MH, et al. Fluoxetine-induced sexual dysfunction. J Clin Psychiatry 1990; 51: 25–27
- Jakobson FM. Fluoxetine-induced sexual dysfunction and an open trial of yohimbine. J Clin Psychiatry 1992; 53: 119–122
- Kleine MD. Fluoxetine and anorgasmia. Am J Psychiatry 1989; 146: 804–805
- Lydiard RB, George MS. Fluoxetine-related anorgasmy. South Med J 1989; 82: 933–934
- Musher JS. Anorgasmia with the use of fluoxetine. Am J Psychiatry 1990; 147: 948
- Davies LP. Fluoxetine-induced lung damage (a comment). Med J Austral 1992; 156: 740
- McCormick S, Olin J, Brotman AW. Reversal of fluoxetine-induced anorgasmia by cyproheptadine in two patients. J Clin Psychiatry 1990; 51: 383–384
- Rodruiguez M, Castro R, Hernandez G, Mas M. Different roles of catecholaminergic and serotonin neurons in the medial forebrain bundle on male rat sexual behavior. Physiol Behav 1984; 33: 5–11
- Hollander E, McCarley A. Yohimbine treatment of sexual side effects induced by serotonin reuptake blockers. J Clin Psychiatry 1992; 53: 207–209
- Riley AJ, Goodman RE, Kellett JM, et al. Double blind trial of yohimbine hydrochloride in the treatment of erection inadequacy. Sex Marit Ther 1989; 4: 17–26
- Sovner R. The use of valproate in the treatment of mentally retarded persons with atypical bipolar disorders. J Clin Psychiatry 1989; 50: 40–43, Suppl
- Feder R. Reversal of antidepressant activity of fluoxetine by cyproheptadine in three patients. J Clin Psychiatry 1991; 52: 163–164
- Balogh S, Hendricks SE, Kang J. Treatment of fluoxetine-induced anorgasmia with amantadine. J Clin Psychiatry 1992; 53: 212–213
- Beraldi M, Bertolini A. Penile erection induced by amantadine in male rats. Life Sci 1974; 14: 1231–1235
- Tonjes R, Gotz F, Maywald J, Dorner G. Influence of a dopamine agonist (Lisuride) on sex-specific behavioral patterns in rats. Exp Clin Endocrinol 1989; 94: 48–54
- Messiha FS. Genotype-treatment interaction between amantadine and chlorpromazine in the mouse. Comp Biochem Physiol 1991; 99C: 323–326
- Messiha FS. Neurotoxicity of chlorpromazine and modulation by amantadine as a function of mouse strain. Neurotoxicology 1991; 12: 571–582
- Neil JR. Penile anesthesia associated with fluoxetine use. Am J Psychiatry 1991; 148: 1603
- Measom MO. Penile anesthesia and fluoxetine. Am J Psychiatry 1992; 149: 709
- Morris P LP. Fluoxetine and orgasmic sexual experiences. Int J Psychiatry Med 1991; 21: 379–389
- Modell JG. Repeated observations of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration. J Clin Psychopharmacol 1989; 9: 63–65
- Klein DF. Repeated observation of yawning, clitoral engorgement, and orgasm associated with fluoxetine administration. J Clin Psychopharmacol 1989; 9: 384
- Bost RO, Kemp PM. A possible association between fluoxetine use and suicide. J Anal Toxicol 1992; 16: 142–145
- Dasgupta K. Additional cases of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990; 147: 1570–1571
- Hoover C. Additional cases of suicidal ideation associated with fluoxetine. Am J Psychiatry 1990; 147: 1571
- Massand P, Gupta S, Dewan M. Suicidal ideation related to fluoxetine treatment. N Engl J Med 1991; 324: 420
- Miller RA. Discussion of fluoxetine and suicidal tendencies. Am J Psychiatry 1990; 147: 1571
- Teicher MH, Glod C, Cole JO. Emergence of intense suicidal preoccupation during fluoxetine treatment. Am J Psychiatry 1990; 147: 207–120
- Beasley CM, Potvin JH, Masica DN, et al. Fluoxetine: No association with suicidality in obsessive-compulsive disorder. J Affective Disord 1992; 24: 1–10
- Fava M, Rosenbaum JF. Suicidality and fluoxetine: Is there a relationship?. J Clin Psychiatry 1991; 52: 108–111
- Greenfield DP, Brown JA. Guest editorial: What about prozac?. N J Med 1992; 89: 445–446
- Mann JJ, Kapur S. The emergence of suicidal ideation and behavior during antidepressant therapy. Arch Gen Psychiatry 1991; 48: 1027–1033
- Wheadon DE, Rampey AH, Thompson VL, et al. Lack of association between fluoxetine and suicidality in bulimia nervosa. J Clin Psychiatry 1992; 53: 235–241
- Pearlman T. Fluoxetine and suicidality. J Clin Psychiatry 1992; 53: 256
- Banki CM, Arato M, Papp Z, Kurcz M. Biochemical markers in suicidal patients. J Affective Disord 1984; 6: 341–350
- López-Ibor JJ. The involvement of serotonin in psychiatric disorders and behavior. Br J Psychiatry Suppl 1988; 153: 26–39
- Markku V, Linnoila I, Virkkunen M. Aggression, suicidality, and serotonin. J Clin Psychiatry 1992; 53: 46–51
- Traskman L, Asberg M, Bertilsson Sjostrand L. Monoamine metabolites in cerebrospinal fluid and suicidal behavior. Arch Gen Psychiatry 1981; 38: 631–636
- Schildkraut J. The catecholamine hypothesis of affective disorders: A review of supporting evidence. Am J Psychiatry 1965; 122: 509–522
- Miller L, Bowman R, Mann D, et al. A case of fluoxetine-induced serum sickness. Am J Psychiatry 1989; 146: 1616–1617
- Olfson M, Wilner M. A family case history of fluoxetine-induced skin reaction. J Nerv Ment Dis 1991; 179: 504–505
- Guthrie S, Grunhaus L. Fluoxetine-induced stuttering. J Clin Psychiatry 1990; 51: 85
- Elliot RR, Thomas BJ. A case report of alprazolam-induced stuttering. J Clin Psychopharmacol 1985; 5: 159–160
- Friedman EH. Fluoxetine and stuttering. J Clin Psychiatry 1990; 51: 310–311
- Garvey MJ, Tollefson GO. Occurrence of myoclonus in patients treated with cyclic antidepressants. Arch Gen Psychiatry 1987; 44: 269–272
- Humphries JE, Wheby MS, Vanden Berg SR. Fluoxetine and the bleeding time. Arch Path Lab Med 1990; 114: 727–728
- Evans TG, Buys SS, Rodgers GM. Letter to the editor. N Engl J Med 1991; 324: 1671
- Gunzberger D, Martinez D. Adverse vascular effects associated with fluoxetine. Am J Psychiatry 1992; 149: 1751
- Yaryura-Tobias J, Kischer H, et al. Fluoxetine and bleeding in obsessive compulsive disorder. Am J Psychiatry 1991; 148: 949
- Aranth J, Lindberg C. Bleeding as a side effect of fluoxetine. Am J Psychiatry 1992; 149: 412
- Steiner W, Fontaine R. Toxic reaction following combined administration of fluoxetine and L-tryptophan in five case reports. Biol Psychiatry 1986; 21: 1067–1071
- Hemlock C, Rosenthal J, Winston A. Fluoxetine-induced psoriasis. Ann Pharmacother 1992; 26: 211–212
- Grady TA, Pigott TA, L'Heureux F, Murphy DL. Seizure associated with fluoxetine and adjunct buspirone therapy. J Clin Psychopharmacol 1992; 12: 70–71
- Wroblewski B, Guidos A, Leary J, Joseph BA. Control of depression with fluoxetine and antiseizure medication in a brain injured patient. Am J Psychiatry 1992; 149: 273
- Ware MR, Stewart RB. Seizures associated with fluoxetine therapy. DICP 1989; 23: 428
- Leander JD. Fluoxetine, a selective serotonin-uptake inhibitor, enhances the anticonvulsant effects of phenytoin, carbamazepine, and ameltolide. Epilepsia 1992; 33: 573–576
- Parker WA. Imipramine-induced syndrome of inappropriate antidiuretic hormone secretion. Drug Intell Clin Pharm 1984; 18: 890–894
- Hwang AS, Magraw RM. Syndrome of inappropriate secretion of antidiuretic hormone due to fluoxetine. Am J Psychiatry 1989; 146: 399
- Staab JP. Transient SIADH associated with fluoxetine. Am J Psychiatry 1990; 147: 1569–1570
- Vishwanath BM, Navalgund A, Cusano W, Navalgund K. Fluoxetine as a cause of SIADH. Am J Psychiatry 1991; 148: 542–543
- Marik PE, Van Harden W, Steenkamp P. Fluoxetine-induced syndrome of inappropriate anti-diuretic hormone excretion. S Afr Med J 1990; 78: 760–761
- Harrison D. Safety of 5-HT reuptake inhibitors. Br J Psychiatry 1992; 160: 866
- Morgan JP, Nathan G, Rivera-Calimlim L, et al. Imipramine interference with levodopa absorption from the gastrointestinal tract in rats. J Pharmacol Exp Ther 1975; 192: 451–457
- Morgan JP, Rivera-Calimlim L, Messiha FS, Sundaresan PR, Trabert N. Imipramine-mediated interference with levodopa absorption from the gastrointestinal tract in man. Neurology 1975; 25: 1029–1034
- Messiha FS, Morgan JP. Imipramine mediated effect on levodopa metabolism in man. Biochem Pharmacol 1974; 23: 1503–1507
- Pinder R, Brogden R, Gawyer R, Speight T, Avery G. Fenfluramine: A review of its pharmacologic properties and its therapeutic efficacy in obesity. Drugs 1975; 10: 241–323
- August G, Raz N, Baird T. Effects of fenfluramine on behavioral, cognitive, and affective disturbances in autistic children. J Autism Devel Dis 1985; 15: 97–106
- Du Verglas C, Banks S, Gruyer K. Clinical effects of fenfluramine on children with autism: A review of the research. J Autism Devel Dis 1988; 18: 297–308
- Stark P, Fuller R, Wong D. The pharmacologic profile of fluoxetine. J Clin Psychiatry 1985; 46(3)7–1113, Sec. 2
- Hollander E, DeCaria C, Schneier F, et al. Fenfluramine augmentation of serotonin reuptake blockade in antiobsessional treatment. J Clin Psychiatry 1990; 51: 119–123
- Butler D, Messiha FS. Alcohol withdrawal and carbamazepine. Alcohol 1986; 3: 113–129
- Pearson HJ. Interaction of fluoxetine with carbamazepine. J Clin Psychiatry 1990; 51: 126
- Jalil P. Toxic reaction following the combined administration of fluoxetine and phenytoin: Two case reports. J Neurol Neurosurg Psychiatry 1992; 55: 412–413
- Feighner JP, Herbstein J, Dambouji N. Combined MAOI, TCA, and direct stimulant therapy of treatment-resistant depression. J Clin Psychiatry, 46: 206–209
- Schmauss M, Kapfhammer HP, Meyr P, et al. Combined MAO-inhibitor and tri-(tetra)cyclic antidepressant treatment in therapy resistant depression: A retrospective study. Pharmacopsychiatry 1986; 19: 251–252
- White K, Simpson G. Combined MAOI-tricyclic antidepressant treatment: A reevaluation. J Clin Psychopharmacol 1981; 1: 264–282
- Oefele K., Grohman R, Ruether E. Adverse drug reactions in combined tricyclic and MAOI therapy. Pharmacopsychiatry 1986; 19: 243–244
- Sternbach H. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 850–851
- Graham PM, Ilett KF. Danger of MAOI therapy after fluoxetine withdrawal. Lancet 1988; 2: 1255–1256
- Benfield P, Heel RC, Lewis SP. Fluoxetine: A review of its pharmacodynamics and pharmacokinetic properties and therapeutic efficacy in depressive illness. Drugs 1986; 32: 481–508
- Medical Letter: Fluoxetine for depression. Med Lett Drugs Ther 1988; 30: 45–47
- Fuller RW, Rathbun RC, Parli CJ. Inhibition of drug metabolism by fluoxetine. Res Comm Chem Path Pharmacol 1976; 13: 353–356
- Elli Lilly Company. Prozac, fluoxetine hydrochloride. Elli Lilly Co., Indianapolis 1987
- Peterson GN. Strategies for fluoxetine-MAOI combination therapy. J Clin Psychiatry 1991; 52: 87
- Ooi TK. The serotonin syndrome. Anaesthesia 1991; 46: 507–508
- Sternbach H. The serotonin syndrome. Am J Psychiatry 1991; 148: 705–713
- Feighner JP, Boyer WF, Tyler DL, Neboisky RJ. Adverse consequences of fluoxetine-MAOI combination therapy. J Clin Psychiatry 1990; 51: 222–225
- Suchowersky O, deVries JD. Interaction of fluoxetine and selegiline. Can J Psychiatry 1990; 35: 571–572
- Menza MA, Golbe LI. Hypomania in a patient receiving deprenyl (selegiline) after adrenal-striatal implantation for Parkinson's disease. Clin Neuropharmacol 1988; 11: 549–551
- Nierenberg AA, Cole JO, Glass L. Possible trazodone potentiation of fluoxetine: A case series. J Clin Psychiatry 1992; 53: 83–85
- Weilburg JB, Rosenbaum JF, Biederman J, et al. Fluoxetine added to non-MAOI antidepressants converts nonresponders to responders: A preliminary report. J Clin Psychiatry 1989; 50: 447–449
- Wright CE, Lasker-Sisson TA, Steenwyk RC, Swanson CN. A pharmacokinetic evaluation of the combined administration of triazolam and fluoxetine. Pharmacother 1992; 12: 103–106
- Goodnick PJ. Pharmacokinetics of second generation antidepressants: Fluoxetine. Psychopharmacol Bull 1991; 27: 503–512
- Montgomery SA, Baldwin D, Shah A, et al. Plasma level response relationships with fluoxetine and zimeldine. Clin Neuropharmacol 1990; 13: S71–75, Suppl
- Nelson JC, Mazure CM, Bowers MB, Jatlow PI. A preliminary open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry 1991; 48: 303–307
- Aranow RB, Huson JI, Pope HG, et al. Elevated antidepressant plasma levels after addition of fluoxetine. Am J Psychiatry 1989; 146: 911–913
- Bell IR, Cole JO. Fluoxetine induces elevation of desipramine level and exacerbation of geriatric nonpsychotic depression. J Clin Psychopharmacol 1988; 8: 447–448
- Bergstrom RF, Peyton AL, Lemberger L. Quantification and mechanism of fluoxetine and tricyclic antidepressant interaction. Clin Pharmacol Ther 1992; 51: 239–248
- Cavanaugh S VA. Drug-drug interactions of fluoxetine with tricyclics. Psychosomatics 1990; 31: 273–276
- Downs JM, Downs AD, Rosenthal TL, et al. Increased plasma tricyclic antidepressant concentration in two patients concurrently treated with fluoxetine. J Clin Psychiatry 1989; 50: 226–227
- Goodnick JP. Influence of fluxetine on plasma levels of desipramine. Am J Psychiatry 1989; 146: 552
- Greenblott DJ, Preskorn SH, Cotreau MM, Horst WD, Harmatz JS. Fluoxetine impairs clearance of alprazolam but not of clonazepam. Clin Pharmacol Ther 1992; 52: 479–486
- Grimsley S, Jann M, Carter J, D'Mello A, D'Souza M. Increased carbamazepine plasma concentrations after fluoxetine coadministration. Clin Pharmacol Ther 1991; 50: 10–15
- Preskorn HJ, Berber J, Faul J, Hirschfeld R. Serious adverse effects of combining fluoxetine and tricyclic antidepressants. Am J Psychiatry 1990; 147: 532
- Vaughan DA. Interaction of fluoxetine with tricyclic antidepressants. Am J Psychiatry 1988; 145: 1478
- Lemberger L, Bergstrom RF, Wolen RL, et al. Fluoxetine: Clinical Pharmacology and Physiologic disposition. J Clin Psychiatry 1985; 46(3)14–19, Sec. 2
- Lemberger L, Rowe H, Bosomworth JC, et al. The effect of fluoxetine on the pharmacokinetics and psychomotor responses of diazepam. Clin Pharmacol Ther 1988; 43: 412–419
- Westermeyer J. Fluoxetine-induced tricyclic toxicity: Extent and duration. J Clin Pharmacol 1991; 31: 388–392
- Spiker DG, Weiss AN, Chang SS, et al. Tricyclic antidepressant overdose: Clinical presentation and plasma levels. Clin Pharmacol Ther 1975; 18: 539–546
- Fuller RW, Perry KW. Effect of fluoxetine pretreatment on plasma and tissue concentrations of desipramine in rats. Res Comm Chem Path Pharmacol 1989; 66: 375–384
- Goff DC, Midha KK, Brotman AW, et al. Elevation of plasma concentrations of haloperidol after the addition of fluoxetine. Am J Psychiatry 1991; 148: 790–794
- Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions I: Antidepressants and antipsychotics. J Clin Psychopharmacol 1990; 10: 48–50
- Ciraulo DA, Shader RI. Fluoxetine drug-drug interactions II. J Clin Psychopharmacol 1990; 10: 213–217
- Bodkin JA, Teicher MH. Fluoxetine may antagonize the anxiolytic action of buspirone. J Clin Psychopharmacol 1989; 9: 150
- Metz A. Interaction between fluoxetine and buspirone. Can J Psychiatry 1990; 35: 722–723
- Tanquary J, Masand P. Paradoxical reaction to buspirone augmentation of fluoxetine. J Clin Psychopharmacol 1990; 10: 377
- Lasher TA, Fleishshaker JC, Steenwyk RC, Antal EJ. Pharmacokinetic pharmacodynamic evaluation of the combined administration of alprazolam and fluoxetine. Psychopharmacology 1991; 104: 323–327
- Friedman EH. The role of the right hemisphere in fluoxetine-induced bradycardia and syncope. J Clin Psychiatry 1991; 52: 138–139
- Zamrini EY, Meador KJ, Loring DW, et al. Unilateral cerebral inactivation produces differential left/right heart rate responses. Neurology 1990; 40: 1408–1411
- Eison MS, Temple DL. Buspirone: Review of its pharmacology and current perspectives on its mechanism of action. Am J Med 1986; 80: 1–9, Suppl
- Perry PJ. Assessment of addiction liability of benzodiazepines and buspirone. Drug Intell Clin Pharmacol 1985; 19: 657–659
- Bakish D. Fluoxetine potentiation by buspirone: Three case histories. Can J Psychiatry 1991; 36: 749–750
- Janike MA, Baer L, Buttolph L. Buspirone augmentation of fluoxetine in patients with obsessive compulsive disorder. J Clin Psychiatry 1991; 52: 13–14
- Gualtieri CT. Paradoxical effects of fluoxetine. J Clin Psychopharmacol 1991; 11: 393–394
- Moskowitz H, Burns M. The effects on performance of two antidepressants, alone and in combination with diazepam. Prog Neuropsychopharmacol Biol Psychiatry 1988; 12: 783–792
- Sternbach H. Fluoxetine-associated potentiation of calcium-channel blockers. J Clin Psychopharmacol 1991; 11: 390–391
- Bansal S, Brown WA. Cyproheptadine in depression. Lancet 1983; 2: 803
- DeCastro DM. Reversal of MAOI-induced anorgasmia with cyproheptadine. Am J Psychiatry 1985; 142: 783
- Sovner R. Treatment of tricyclic antidepressant-induced orgasmic inhibition with cyproheptadine. J Clin Psychopharmacol 1984; 4: 169
- Steele TE, Howell EF. Cyproheptadine for imipramine-induced anorgasmia. J Clin Psychopharmacol 1986; 6: 326–327
- Turner SM, Jacob RG, Beidel DC, Griffin S. A second case of mania associated with fluoxetine. Am J Psychiatry 1985; 142: 274–275
- De Montigny C, Grunberg F, Mayer A, et al. Lithium induces rapid relief of depression in tricyclic antidepressant drug non-responders. Br J Psychiatry 1981; 138: 252–256
- Heninger GR, Charney DS, Sternberg DE. Lithium carbonate augmentation of antidepressant treatment: An affective treatment for treatment refractory depression. Arch Gen Psychiatry 1983; 40: 1335–1342
- Howland RH. Lithium augmentation of fluoxetine in the treatment of OCD and major depression: A case report. Can J Psychiatry 1991; 36: 154–155
- Lafferman J, Solomon K, Ruskin P. Lithium augmentation for treatment-resistant depression in the elderly. J Geriat Psychiatry Neurol 1988; 1: 49–52
- Ontiveros A, Fontaine R, Elie R. Refractory depression: The addition of lithium to fluoxetine or desipramine. Acta Psychiatr Scand 1991; 83: 188–192
- Pope HG, McElroy S, Nixon R. Possible synergism between fluoxetine and lithium in refractory depression. Am J Psychiatry 1988; 145: 1292–1294
- Price LH. Lithium augmentation in tricyclic-resistant depression. Treatment of Trycyclic Resistant Depression, IL Extein. American Psychiatric Press, Washington, DC 1989; 49–79
- Schöepf J. Treatment of depression resistant to tricyclic antidepressants, related drugs of MAO-inhibitors by lithium addition: Review of the literature. Pharmacopsychiatry 1989; 2: 174–182
- Blier P, De Montigny C. Short-term lithium administration enhances serotonergic neurotransmission: Electrophysiological evidence in the rat CNS. Eur J Pharmacol 1985; 113: 67–77
- Rasumussen S, Keitner G. Tricyclic antidepressants. Lithium Combination Treatments, FN Johnson. Karger Pub, New York 1987
- Salama AA, Shafey M. A case of severe lithium toxicity induced by combined fluoxetine and lithium carbonate. Am J Psychiatry 1989; 146: 278
- Noveske FG, Hahn KR, Flynn RJ. Possible toxicity of combined fluoxetine and lithium. Am J Psychiatry 1989; 146: 1515
- Price LH, Charney DC, Heninger GR. Variability of response of lithium augmentation in refractory depression. Am J Psychiatry 1986; 143: 1387–1392
- Damluji NF, Ferguson JM. Paradoxical worsening of depressive symptomatology caused by antidepressants. J Clin Psychopharmacol 1988; 8: 345–349
- Sacristan JA, Iglesias C, Arellano F, Lequerica J. Absence seizures induced by lithium: Possible interaction with fluoxetine. Am J Psychiatry 1991; 148: 146–147
- Stoll AL, Cole JO, Lukas SE. A case of mania as a result of fluoxetine-marijuana interaction. J Clin Psychiatry 1991; 52: 280–281
- Thornicraft G. Cannabis and Psychosis: Is there epidemiological evidence for association?. Br J Psychiatry 1990; 157: 25–33
- Gorelick DA, Paredes A. Effect of fluoxetine on alcohol consumption in male alcoholics. Alcohol Clin Exp Res 1992; 16: 261–265
- Naranjo CA, Kadlee K, Sanhueza E, et al. Fluoxetine differentially alters alcohol intake and other consummatory behaviors in problem drinkers. Clin Pharmacol Ther 1990; 47: 490–498
- Rohrig TP, Prouty RW. Fluoxetine overdose: A case report. J Anal Toxicol 1989; 13: 305–307
- Allen D, Lader M. Interaction of alcohol with amitriptyline, fluoxetine and placebo in normal subjects. Int Clin Psychopharmacol 1989; 4: 7–14
- Picker W, Lerman A, Hajal F. Potential interaction of LSD and Fluoxetine. Am J Psychiatry 1991; 148: 843–844
- Hersh CB, Sokol MS, Pfeffer CR. Transient psychosis with fluoxetine. J Am Acad Child Adoles Psychiatry 1991; 30: 851–852
- Achamallah NS. Visual hallucination after combining fluoxetine and dextromethorphan. Am J Psychiatry 1992; 149: 1406
- Walters AM. Sympathomimetic-fluoxetine interaction. J Am Acad Child Adoles Psychiatry 1992; 31: 565–566
- Rowe H, Carmichael R, Lemberger L. The effect of fluoxetine on warfarin metabolism in the rat and man. Life Sci 1978; 23: 807–812
- Claire RJ, Servis ME, Cram DL. Potential interaction between warfarin sodium and fluoxetine. Am J Psychiatry 1991; 148: 1604
- Hansen TE, Dieter K, Keepers GA. Interaction of fluoxetine and pentazocine. Am J Psychiatry 1990; 147: 949–950
- Brown R. U.S. experience with valproate in manic depressive illness: A multicenter trial. J Clin Psychiatry 1989; 50: 13–16, Suppl
- Fawcett J. Valproate use in acute mania and bipolar disorder: An International perspective. J Clin Psychiatry 1989; 50: 10–12, Suppl
- Sovner R, Davis JM. A potential drug interaction between fluoxetine and valproic acid. J Clin Psychopharmacol 1991; 11: 389
- Roy-Byrne PP, Ward NG. Valproate in anxiety and withdrawal syndrome. J Clin Psychiatry 1989; 50: 44–48, Suppl
- McElroy SL, Keck PE, Pope HG, Huson JI. Valproate in psychiatric disorders: Literature review and clinical studies. J Clin Psychiatry 1989; 50: 23–29, Suppl
- McFarland B, Miller M, Straumfjord A. Valproate use in the older manic patient. J Clin Psychiatry 1990; 51: 479–481
- Gualtier CT. Paradoxical effects of fluoxetine. J Clin Psycopharmacol 1991; 11: 393–394
- Liebowitz M, Holandee E, Schneier F, et al. Fluoxetine treatment of obsessive compulsive disorder: An open clinical trial. J Clin Psychopharmacol 1989; 9: 423–427
- Dorval GS, Meinzer AE. Appearance of obsessive-compulsive symptoms in depressed patients treated with fluoxetine. Am J Psychiatry 1991; 148: 1262–1263
- Batki SL, Manfredi L, Sorensen J, Dumontet R, Jones R. Fluoxetine for cocaine abuse in methadone patients: Preliminary findings. Nat Inst Drug Abuse Res Monog 1991; 105: 516–517
- Pollack MH, Rosenbaum JF. Fluoxetine treatment of cocaine abuse in heroin addicts. J Clin Psychiatry 1991; 52: 31–33
- Goldman M, Grinspoon L, Hunter-Jones S. Ritualistic use of fluoxetine by a former substance abuser. Am J Psychiatry 1990; 147: 1377
- Como PG, Kurlan R. An open-label trial of fluoxetine for obsessive-compulsive disorder in Gilles de la Tourette's syndrome. Neurology 1991; 41: 872–874
- Cunningham M, Cunningham K, Lydiard RB. Eye tics and subjective hearing impaired during fluoxetine therapy. Am J Psychiatry 1990; 147: 947–948
- Van Woert MH, Magnussen I, Rosenbaum D, Chung E. Fluoxetine in the treatment of intention myoclonus. Clin Neuropharmacol 1983; 6: 49–54
- Insel TR, Roy BF, Cohen RM, et al. Possible development of the serotonin syndrome in man. Am J Psychiatry 1982; 139: 954–955
- Kline SS, Mauro LS, Scala-Barnett DM, Zick D. Serotonin syndrome versus neuroleptic malignant syndrome as a cause of death. Clin Pharm 1989; 8: 510–514
- Sandy RR. L-dopa induced “serotonin syndrome” in a parkinsonian patient on bromocriptine. J Clin Psychopharmacol 1986; 6: 194–195
- Wernicke JF. The side effect profile and safety of fluoxetine. J Clin Psychiatry 1985; 46(Sec. 2)59–67
- Montgomery SA. Venlafaxine: A new dimension in antidepressant pharmacotherapy. J Clin Psychiatry 1993; 54: 119–126